Osteocalcin Ameliorates Motor Dysfunction in a 6-Hydroxydopamine-Induced Parkinson’s Disease Rat Model Through AKT/GSK3β Signaling
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Osteoblasts derived osteocalcin (OCN) is recently reported to be involved in dopaminergic neuronal development. As dopaminergic neuronal injury in the substantia nigra (SN) is a pathological hallmark of Parkinson’s disease (PD), we investigated whether OCN could exert protective effects on 6-hydroxydopamine (6-OHDA)-induced PD rat model. Our data showed that the OCN level in the cerebrospinal fluid in PD rat models was significantly lower than that in controls. Intervention with OCN could improve the behavioral dysfunction in PD rat models and reduce the tyrosine hydroxylase loss in the nigrostriatal system. In addition, OCN could inhibit the astrocyte and microglia proliferation in the SN of PD rats. In vitro studies showed that OCN significantly ameliorated the neurotoxicity of 6-OHDA through the AKT/GSK3β signaling pathway. In summary, OCN plays a protective role against parkinsonian neurodegeneration in the PD rat model, suggesting a potential therapeutic use of OCN in PD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neurotoxic reactive astrocytes are induced by activated microglia
Liddelow, S. A., Guttenplan, K. A., Clarke, L. E., Bennett, F. C., Bohlen, C. J., Schirmer, L., Bennett, M. L., Münch, A. E., Chung, W.-S., Peterson, T. C., et al. (2017) · Nature · doi:10.1038/nature21029 · Cited by 7,971
MDS clinical diagnostic criteria for Parkinson’s disease
Postuma, R. B., Berg, D., Stern, M., Poewe, W., Olanow, C. W., Oertel, W., Obeso, J., Marek, K., Litvan, I., Lang, A. E., et al. (2015) · Movement Disorders · doi:10.1002/mds.26424 · Cited by 7,653
Tansey, M. G., & Goldberg, M. S. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.11.004 · Cited by 1,045
Obeso, J. A., Stamelou, M., Goetz, C. G., Poewe, W., Lang, A. E., Weintraub, D., Burn, D., Halliday, G. M., Bezard, E., Przedborski, S., et al. (2017) · Movement Disorders · doi:10.1002/mds.27115 · Cited by 859 · cited 1×
“Parkinson’s disease (PD) is one of the most common neurodegenerative diseases characterized by cardinal movement disorders, including bradykinesia, tremor and rigidity (Postuma et al., 2015; Obeso et al., 2017), and its nonmotor symptoms, such as cognitive dysfunction, are also increasingly recognized (Crowley et al.”
BackgroundThe Role of Astrocyte Dysfunction in Parkinson’s Disease Pathogenesis
Booth, H. D. E., Hirst, W. D., & Wade-Martins, R. (2017) · Trends in Neurosciences · doi:10.1016/j.tins.2017.04.001 · Cited by 633
Endocrine Regulation of Male Fertility by the Skeleton
Oury, F., Sumara, G., Sumara, O., Ferron, M., Chang, H., Smith, C. E., Hermo, L., Suarez, S., Roth, B. L., Ducy, P., et al. (2011) · Cell · doi:10.1016/j.cell.2011.02.004 · Cited by 628
Why Don't We Move Faster? Parkinson's Disease, Movement Vigor, and Implicit Motivation
Mazzoni, P., Hristova, A., & Krakauer, J. W. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.0264-07.2007 · Cited by 557
Maternal and Offspring Pools of Osteocalcin Influence Brain Development and Functions
Oury, F., Khrimian, L., Denny, C. A., Gardin, A., Chamouni, A., Goeden, N., Huang, Y.-Y., Lee, H., Srinivas, P., Gao, X.-B., et al. (2013) · Cell · doi:10.1016/j.cell.2013.08.042 · Cited by 484 · cited 5×
“OCN could also enhance the synthesis of other monoamine neurotransmitters, such as serotonin and norepinephrine, while inhibiting GABA production by regulating the expression of the key enzymes implicated in the synthesis of these neurotransmitters, with the consequence of preventing anxiety and favoring spatial learn…”
BackgroundResultInfluentialGpr158 mediates osteocalcin’s regulation of cognition
Khrimian, L., Obri, A., Ramos-Brossier, M., Rousseaud, A., Moriceau, S., Nicot, A.-S., Mera, P., Kosmidis, S., Karnavas, T., Saudou, F., et al. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20171320 · Cited by 308
Microglial phenotypes in Parkinson’s disease and animal models of the disease
Joers, V., Tansey, M. G., Mulas, G., & Carta, A. R. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.04.006 · Cited by 285 · cited 1×
“These observations may have clinical implications, since there were reports that suppressing the activation and proliferation of microglia can reverse dopaminergic neuron dysfunction and improve PD symptoms (Joers et al., 2017).”
Background
Cited by
Hou, Y.-F., Shan, C., Zhuang, S.-Y., Zhuang, Q.-Q., Ghosh, A., Zhu, K.-C., Kong, X.-K., Wang, S.-M., Gong, Y.-L., Yang, Y.-Y., et al. (2021) · Microbiome · doi:10.1186/s40168-020-00988-6 · Cited by 231
Self-citationBone-derived factors mediate crosstalk between skeletal and extra-skeletal organs
He, T., Qin, L., Chen, S., Huo, S., Li, J., Zhang, F., Yi, W., Mei, Y., & Xiao, G. (2025) · Bone Research · doi:10.1038/s41413-025-00424-1 · Cited by 58
Shan, C., Zhang, D., Ma, D.-N., Hou, Y.-F., Zhuang, Q.-Q., Gong, Y.-L., Sun, L.-H., Zhao, H.-Y., Tao, B., Yang, Y.-Y., et al. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01343-y · Cited by 53
Self-citation
Metadata
- Authors
- Guo, X.-Z., Shan, C., Hou, Y.-F., Zhu, G., Tao, B., Sun, L.-H., Zhao, H.-Y., Ning, G., Li, S.-T., & Liu, J.-M.
- Venue
- Frontiers in Molecular Neuroscience
- Publisher
- Frontiers Media SA
- Published
- 2018-09-27
- Volume
- 11
- Pages
- 343-343
- ISSN
- 1662-5099 (ISSN-L)
- OpenAlex
- W2892977701
- Cited by
- 48
- References
- 18
- FWCI
- 2.22
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Osteocalcin Ameliorates Motor Dysfunction in a 6-Hydroxydopamine-Induced Parkinson’s Disease Rat Model Through AKT/GSK3β Signaling. https://app.cochat.ai/papers/10.3389/fnmol.2018.00343
- The paper
- Guo, X.-Z., Shan, C., Hou, Y.-F., Zhu, G., Tao, B., Sun, L.-H., Zhao, H.-Y., Ning, G., Li, S.-T., & Liu, J.-M. (2018). Osteocalcin Ameliorates Motor Dysfunction in a 6-Hydroxydopamine-Induced Parkinson’s Disease Rat Model Through AKT/GSK3β Signaling. Frontiers in Molecular Neuroscience. https://doi.org/10.3389/fnmol.2018.00343
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.